Home > Focus Areas > Obesity Connect > Post
  • Saved

6d
Dual incretin-based pharmacotherapy in obesity: Cochrane evidence, cardiovascular outcomes, and evolving European treatment frameworks

Obesity is a chronic, multifactorial disease associated with major cardiometabolic comorbidities and impaired quality of life. Dual GIP/GLP-1 receptor agonist pharmacotherapy has achieved substantially greater medically managed weight loss than previously available agents.

A Cochrane systematic review and meta-analysis of nine RCTs (7,111 participants) demonstrates that a dual GIP/GLP-1 receptor agonist administered weekly achieves approximately 16% body weight reduction versus placebo at 12–18 months (moderate-certainty evidence), sustained at 3.5 years, with no significant difference in major adverse cardiovascular events. The European Association for the Study of Obesity is developing a GRADE-based pharmacological framework evaluating approved obesity agents across individualized subgroups, including patients with type 2 diabetes, cardiovascular disease, sleep apnea, and metabolic liver disease, to provide clinically applicable, person-centered guidance.

Endocrinologists, obesity medicine specialists, cardiologists, and primary care physicians managing obesity will benefit from peer discussion of dual incretin pharmacotherapy evidence, individualized patient selection, combination with lifestyle modification, and long-term weight maintenance.

How do you incorporate dual GIP/GLP-1 receptor agonist therapy into your obesity management algorithm, and what patient-specific factors, including cardiovascular risk, diabetes status, or prior treatment response, guide agent selection? What are the most significant clinical challenges in sustaining long-term weight loss with pharmacological therapy for obesity, and how do you manage treatment discontinuation or weight regain?

Profile Image
  • Uploads
  • 6d
    I offer it to all patients desiring weight loss with BMI more than 30 and no contra-indications like MEN and pancreatitis history. DM, CVD, OSA, NASH are also strong indicators to offer dual GIP/GLP-1. Important to discuss dietary and portion changes along with increasing physical activity as important to maintaining the weight loss and added benefits
  • 1w
    I try to start patients on these preferentially, but especially when they have underlying DM2, CVD, MASH/MASLD, or renal disease. Patient consistency with therapy, side effects, as well as not applying consistent lifestyle changes in addition to medication compliance, present the most clinical barriers to seeing more weight loss success. I usually try switching between brand options to see if patents have more benefit and less side effects, but typically try to keep them on GLP1 therapies if they don't have a major complication.
  • 1w
    With the approval of Wegovy by Medicare for Obesity with high risk for CVD it has been a game changer where as have Ozempic and Mounjoro already in use for Diabetes it has opened up a whole new avenue and with Medcare Bridge Program for &50 a month has reinforced it signficantly ! Weight loss remains a challenge with or with out these meds and most important aspect is continous motivation and education to follow a good diet and exercise program and use these meds cognitively and get conditioned to the early satiety and reduce the "food noise "Choice is what is most affordable and what is most tolerated and I believe all can work if pt follows them in a cogntive manner , However switching back and forth different preps at times gives lot more room for these meds to be effective , discontinualtion is relative some need to sta on low dose and some can off completly
  • 1w
    With the approval of Wegovy by Medicare for Obesity with high risk for CVD it has been a game changer where as have Ozempic and Mounjoro already in use for Diabetes it has opened up a whole new avenue and with Medcare Bridge Program for &50 a month has reinforced it signficantly ! Weight loss remains a challenge with or with out these meds and most important aspect is continous motivation and education to follow a good diet and exercise program and use these meds cognitively and get conditioned to the early satiety and reduce the "food noise "Choice is what is most affordable and what is most tolerated and I believe all can work if pt follows them in a cogntive manner , However switching back and forth different preps at times gives lot more room for these meds to be effective , discontinualtion is relative some need to sta on low dose and some can off completly
  • 1w
    insurance and coverage is always going to be a factor when incorporating these medications for weight loss but even if you meet guidelines for cardiometabolic syndrome insurance still may not cover, more help for patients with dm and heart disease or renal disease than coverage expands, compliance with the medications and giving self injections are a important conversation to have because that's going to determine the efficacy in these patients and obesity is multifactorial so other factors should be addressed (psycho-social) and this is life long
  • 1w
    insurance and coverage is always going to be a factor when incorporating these medications for weight loss but even if you meet guidelines for cardiometabolic syndrome insurance still may not cover, more help for patients with dm and heart disease or renal disease than coverage expands, compliance with the medications and giving self injections are a important conversation to have because that's going to determine the efficacy in these patients and obesity is multifactorial so other factors should be addressed (psycho-social) and this is life long
  • 2w
    Dual GIP/GLP-1 receptor agonist therapy (tirzepatide) is positioned as a first-line pharmacologic option co-equal with semaglutide for adults with obesity or overweight with weight-related comorbidity, and is chosen preferentially when the goal is maximal weight loss, given its superior efficacy in both head-to-head observational data and network meta-analyses.
    However, semaglutide currently carries stronger evidence for reducing MACE and all-cause mortality, so agent selection hinges on whether the dominant clinical priority is weight/metabolic reduction versus proven cardiovascular event reduction.
    Because obesity is a chronic relapsing disease, all of these agents are intended as long-term therapy; discontinuation reliably produces regain of one-half to two-thirds of lost weight within about a year, with reversal of cardiometabolic gains.
  • 3w
    Patients with Obesity class 2 or 3 benefit from dual GLP1/GIP therapy as weight loss is more pronounced with Zepbound as compared to GLP1 based treatments. Zepbound is also indicated for patients with OSA and it is often easier to get it authorized in this category of patients
  • 3w
    Dual GIP/GLP therapy would be very beneficial for morbidly obese patients even without major comorbid conditions and obese patients with major comorbid coverage will affect usage.
    Unless life style changes are made by patients stopping treatment would not be possible

    • Welcome to conditions.in

    Source : https://www.conditions.in

    Welcome to conditions.in

  • 3w
    Will use the GLP/GIP first line in sleep apnea and for BMI over 40 and per patient preference after that.
    Clinical challenges include cost and coverage and avoiding rapid weight loss, retaining muscle and eventual stopping when goal weight is reached.
    As far as discontinuation it's multifactorial. sometimes it's change to lifestyle sometimes it's dose adjustment or interval adjustment
  • 4w
    consider dual GIP/GLP-1 receptor agonists for adults with obesity, especially those with type 2 diabetes or other cardiometabolic risk factors, alongside lifestyle changes. My choice depends on the patient’s weight-loss goals, cardiovascular and metabolic health, previous treatment response, side effect profile, preferences, and cost. The biggest challenges are long-term adherence, gastrointestinal side effects, access, and weight regain after stopping treatment. I address these by providing ongoing lifestyle support, regular follow-up, setting realistic expectations, and developing a long-term maintenance plan tailored to the individual.

Show More Comments